71 related articles for article (PubMed ID: 3661768)
1. Abnormal prolactin response to haloperidol challenge in men with schizophrenia.
Keks NA; Copolov DL; Singh BS
Am J Psychiatry; 1987 Oct; 144(10):1335-7. PubMed ID: 3661768
[TBL] [Abstract][Full Text] [Related]
2. Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects.
Copolov DL; Keks NA; Kulkarni J; Singh BS; McKenzie D; McGorry P; Hill C
Psychoneuroendocrinology; 1990; 15(3):225-31. PubMed ID: 2255750
[TBL] [Abstract][Full Text] [Related]
3. Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems.
Keks NA; Copolov DL; Kulkarni J; Mackie B; Singh BS; McGorry P; Rubin RT; Hassett A; McLaughlin M; van Riel R
Biol Psychiatry; 1990 Jun; 27(11):1203-15. PubMed ID: 2354227
[TBL] [Abstract][Full Text] [Related]
4. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
[No Abstract] [Full Text] [Related]
5. Prolactin response to single and multiple doses of haloperidol in schizophrenic patients.
Ravichandran GK; Lu RB; Shvartsburd A; Misra CH; Ho BT; Kahn M; Smith RC
Psychiatry Res; 1984 Jan; 11(1):61-9. PubMed ID: 6584932
[TBL] [Abstract][Full Text] [Related]
6. Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia.
Mohr P; Horácek J; Motlová L; Libiger J; Czobor P
Psychopharmacology (Berl); 1999 Jan; 141(3):322-5. PubMed ID: 10027514
[TBL] [Abstract][Full Text] [Related]
7. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
[TBL] [Abstract][Full Text] [Related]
8. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
9. Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients.
Keks NA; McKenzie DP; Low LH; McGorry PD; Hill C; Kulkarni J; Singh BS; Copolov DL
Biol Psychiatry; 1992 Sep; 32(5):426-37. PubMed ID: 1486148
[TBL] [Abstract][Full Text] [Related]
10. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S
Psychopharmacology (Berl); 2002 Jun; 162(1):63-6. PubMed ID: 12107619
[TBL] [Abstract][Full Text] [Related]
11. Haloperidol and droperidol treatment in schizophrenics. Clinical application of the "prolactin-model".
Langer G; Pühringer W
Acta Psychiatr Belg; 1980; 80(5):574-83. PubMed ID: 7234451
[TBL] [Abstract][Full Text] [Related]
12. Submaximal plasma prolactin response to TRH and dopamine activity in man.
Spoov J
Pharmacopsychiatry; 1985 Nov; 18(6):330-2. PubMed ID: 3003766
[TBL] [Abstract][Full Text] [Related]
13. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
[TBL] [Abstract][Full Text] [Related]
14. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic factors in human prolactin regulation: a pituitary model for the study of a neuroendocrine system in man.
Langer G; Sachar EJ; Nathan RS; Tabrizi MA; Perel JM; Halpern FS
Psychopharmacology (Berl); 1979 Oct; 65(2):161-4. PubMed ID: 117485
[TBL] [Abstract][Full Text] [Related]
16. [Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride].
Liu KL; Lung FW
Kaohsiung J Med Sci; 1996 Dec; 12(12):685-90. PubMed ID: 9011126
[TBL] [Abstract][Full Text] [Related]
17. REM sleep and prolactin in patients with non-affective psychoses.
Appelberg B; Katila H; Rimón R
Psychoneuroendocrinology; 2002 Aug; 27(6):661-9. PubMed ID: 12084659
[TBL] [Abstract][Full Text] [Related]
18. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
[TBL] [Abstract][Full Text] [Related]
19. Variability of prolactin response to intravenous and intramuscular haloperidol in normal adult men.
Rubin RT; Hays SE
Psychopharmacology (Berl); 1979 Mar; 61(1):17-24. PubMed ID: 108715
[TBL] [Abstract][Full Text] [Related]
20. The effect of haloperidol on aldosterone secretion.
Warner MD; Gillespie H; Pavlou SN; Nader S; Peabody CA
Psychoneuroendocrinology; 1992 Oct; 17(5):517-21. PubMed ID: 1484918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
